> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # The $77M Bet on Proximity: InduPro's Bispecific ADC Enters the Clinic - URL: https://nexi.fund/indupro-bispecific-adc-series-b-2026/ - Published: 2026-08-18T10:00:34.000Z - Updated: 2026-08-18T10:00:34.000Z - Description: InduPro raised $77M led by The Column Group — with Merck, Sanofi, Lilly, Vida Ventures, Emerson Collective, Euclidean Capital and Solasta Ventures — the same day its proximity-guided bispecific ADC IDP-001 (EGFR×TAPA-E1) dosed its first patient. Why spatial targeting matters now. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-number, #track-E The number on the wire is $77 million. That is what a Series B costs when you take a first-in-class antibody-drug conjugate into its first patient. InduPro closed the round and dosed that patient on the same day, August 12. 🎯 **IDP-001, a potential first-in-class bispecific antibody-drug conjugate (ADC) built on spatial proximity, dosed its first patient in a Phase 1 study (NCT07602842) on August 12, 2026.** The $77M Series B pools Merck, Sanofi and Eli Lilly strategic funds with The Column Group and Vida Ventures, an unusual big-pharma cluster for a Phase 1 company. Its proximity-labeling platform was invented inside Merck's own exploratory science center; Merck backs the company and runs a separate bispecific-discovery collaboration valued at up to roughly $950 million. The context is squamous cancers. Many of the advances that reshaped other solid tumors skipped them: no driver mutation to hit, no approved ADC target on the cell surface in most cases. InduPro's argument is that the biology of the tumor surface, mapped as a spatial map rather than a list of markers, opens a way in. ## Seventy-seven million dollars, one syringe InduPro is a Seattle and Cambridge, Massachusetts biotech that translates the spatial layout of membrane proteins into drug targets. It builds bispecific antibodies, ADCs and T-cell engagers for oncology and autoimmune disease. The Series B closed and the first patient was dosed on the same day, and the sequencing is deliberate: the money funds the trial, and the trial is what the money is for. The syndicate reads like a shortlist of strategic desire. The Column Group led. Existing backers Vida Ventures, MRL Ventures Fund, the therapeutics arm of Merck & Co., Emerson Collective and Euclidean Capital came back in. New money came from Solasta Ventures, Sanofi and Eli Lilly. Terms beyond the headline were not disclosed. $77M Series B, August 2026 #### InduPro Series B, closed same day first patient dosed Round led by The Column Group; Merck, Sanofi and Eli Lilly strategic funds participate. Proceeds fund the IDP-001 Phase 1 program and preclinical pipeline. · *Business Wire / AllSci, 2026* ## A bispecific that earns its specificity Conventional ADCs attach one antibody to a cytotoxic payload and depend on the target being abundant on the tumor. EGFR is a proven oncogene, but EGFR-targeting ADCs have a history of a different kind. The receptor is also on normal tissue, and the balance between tumor effect and on-target toxicity has limited the class. That is the gap IDP-001 is built for. IDP-001 binds EGFR and TAPA-E1, a tumor-associated proximity antigen the company found by mapping which proteins sit physically adjacent to EGFR on the surface of tumor cells, not which ones are merely co-expressed. The drug's specificity claim rests on the pair appearing together only on tumors. The company calls the discovery engine MInt, a membrane interactomics platform built on proximity-labeling proteomics. Preclinical data add shape. In vitro, IDP-001 showed activity across cancer lines with different target-expression levels, including osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC), and minimal activity against normal cells carrying both targets. It uses a monomethyl auristatin E (MMAE) payload at a low drug-to-antibody ratio. Xenograft studies showed antitumor effect. #### Why not just another EGFR-targeting ADC? Earlier EGFR-directed ADCs struggled to turn target density into a safe dose. Dual targeting of EGFR and TAPA-E1 is designed to increase tumor selectivity and internalization while preserving tolerability, effectively making the dose window wider rather than pushing for more payload. First-in-human data will test whether that hypothesis holds. **Confirmation criteria:** a Phase 1 dose range without dose-limiting on-target toxicity and signs of antitumor activity. > "The targets for our bispecific ADC were selected based not only on their shared biology across squamous tumors, but also on their proximity on the surface of cancer cells, a spatial relationship not found in normal tissue."— Amanda J. Redig, Chief Medical Officer, InduPro ## Strategic pharma interest on multiple fronts A company that maps the tumor surface as a neighborhood is not a random project. InduPro’s proximity-labeling technology was invented at the Merck Exploratory Science Center, and co-founders Rob Oslund and Niyi Fadeyi came out of it. MRL Ventures Fund, Merck’s therapeutics venture arm, is in the Series B. In parallel, InduPro runs a separate collaboration with Eli Lilly, valued at up to roughly $950 million in milestones, to discover bispecific and multispecific oncology therapeutics. | Dimension | Conventional ADC | Proximity-based bispecific ADC | | ----------------- | ------------------------------------------ | ----------------------------------------------------------------- | | **Target logic** | Single antigen, chosen by expression level | Co-target pair, chosen by physical adjacency on the tumor surface | | **Tolerability** | On-target toxicity often limits the dose | Dual binding designed to widen the therapeutic window | | **Evidence base** | Validated targets, multiple approved drugs | First-in-class claim, Phase 1 readout still pending | AllSci / company release, 2026 Industry trackers count roughly 211 bispecific ADCs in development, per a survey from June 2026, with only a handful in Phase 3 and not a single one approved anywhere. The modality is young enough that platform economics, not sales, carry the valuation conversation. That makes the series of milestones here unusually legible: dose escalation in 2027, then early efficacy, then the real question of whether the spatial hypothesis survives contact with a bigger sample. ## What happens to ADC deal flow a year from now? 🔮 **By mid-2027, at least two more proximity-guided bispecific ADC programs will enter the clinic, and at least one large pharmaceutical company will take a platform-level license in the space.** Probability: 60%. Three pharma strategic funds already wrote checks into one round, and the constraint this modality addresses, EGFR-class on-target toxicity, is well documented. #### ✅ Arguments for Strategic capital is clustering around the modality; a $950M collaboration structure already exists between the company and Merck; the field has expanded to over 200 programs from near zero in four years. **Confirmation criteria:** a second Phase 1 proximity-based bispecific ADC start in the next 12 months, or a licensing deal built on a proximity-mapping platform. #### ❌ Arguments against No bispecific ADC is approved anywhere, which caps near-term commercial comparisons; first-in-class biology fails at proof-of-concept more often than it succeeds; Phase 1 monotherapy readouts take 18 to 24 months, longer than deal-flow enthusiasm lasts. **Disconfirmation criteria:** a complete or partial response rate near zero at the first efficacy look, or a prominent developer exiting the modality. ### Development scenarios #### 🟢 Optimistic scenario (35%) IDP-001 shows early antitumor activity in a tolerable dose range. Platform credibility jumps, the Merck collaboration gets exercised deeper, and a Series C prices meaningfully higher than the $77M round. **Implications:** proximity mapping becomes a named feature of ADC diligence, not a footnote. #### 🟡 Base-case scenario (45%) The typical Phase 1 course: safety manageable, efficacy signal mixed, program advances to dose expansion. Valuation holds roughly flat until Phase 2 data arrive. **Implications:** the company stays a private platform bet; the strategic syndicate remains the primary audience for its equity. #### 🔴 Pessimistic scenario (20%) Tolerability or pharmacokinetic problems surface, or the proximity hypothesis fails to translate in humans. The program stalls; the syndicate steadies the company behind the remaining pipeline. **Implications:** a re-rating of spatial biology as a drug-discovery idea, not a drug-delivery one. These numbers do not come from a model. They are a description of how investor attention behaves when a novel modality meets a single-arm readout: big when the biology fits the story, impatient when it does not. As we wrote in August, Ratio Therapeutics raised $70 million for actinium-225, a radioactive payload with a two-centimetre range. InduPro's $77 million is a similar bet on a different targeting logic: radioactivity in one case, spatial biology in the other. Neither molecule has read out yet, which is why the right posture is to watch both rather than judge them. 📊 **Key signals to track** Any disclosed dose-escalation data from NCT07602842 in 2027, particularly the dose-limiting toxicity profile. Movement in the Merck collaboration: added programs or realized milestones under the \~$950M ceiling. Whether TAPA discovery extends beyond oncology into the company's stated autoimmune arena. The pricing of a future financing within 18 months, which acts as the market's verdict on the modality. [ InduPro banks $77m series B as lead ADC enters the clinic Trade-press rundown of the round, the syndicate, and InduPro's spatial-arrangement positioning for its bispecific ADC. The Pharma Letter ](https://www.thepharmaletter.com/biotech-news/indupro-banks-77-million-series-b-as-lead-adc-enters-the-clinic?ref=nexi.fund) Independent editorial framing of the deal, the most balanced secondary source in the set. [ InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 The primary announcement: round details, study design, and quotes from InduPro leadership and its board chair. Yahoo Finance ](https://finance.yahoo.com/healthcare/articles/indupro-closes-77-million-series-113000456.html?ref=nexi.fund) Primary source for the trial design, quotes, and syndicate composition. [ InduPro raises USD 77m as proximity-guided bispecific ADC enters clinic Adds the technical depth the press release leaves out: the MInt platform, the TAPA-E1 target, the MMAE payload, and the origin of the technology at Merck. AllSci ](https://allsci.com/news/venture-financing/indupro-series-b-funding-adc-advances?ref=nexi.fund) Source for the platform mechanics and the founders' provenance.